Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5377317 | 0.94 | CNR1 (0.42) | CNR1CNR2KCNH2ALDH1A1CYP2D6 | |
| SCHEMBL5372812 | 0.92 | CNR1 (0.42) | CNR1CNR2KCNH2ADORA3ADORA1 | |
| SCHEMBL5379142 | 0.89 | CNR1 (0.47) | CNR1CNR2KCNH2 | |
| SCHEMBL5382610 | 0.88 | CNR1 (0.41) | CNR1CNR2KCNH2 | |
| SCHEMBL5375528 | 0.87 | CNR1 (0.39) | CNR1CNR2KCNH2 | |
| SCHEMBL5375366 | 0.85 | CNR1 (0.42) | CNR1CNR2KCNH2ALDH1A1 | |
| SCHEMBL5373810 | 0.83 | CNR1 (0.52) | CNR1CNR2KCNH2 | |
| SCHEMBL5368415 | 0.83 | CNR1 (0.40) | CNR1CNR2KCNH2 | |
| SCHEMBL5432016 | 0.83 | CNR1 (0.45) | CNR1CNR2ALDH1A1CYP2D6 | |
| SCHEMBL27636190 | 0.82 | CNR1 (0.40) | CNR1CNR2KCNH2ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | claimed |
| US-20040248881-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-09 | — | — | US | claimed |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CARPINO PHILIP A | 2007-09-13 | — | — | US | disclosed |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CARPINO PHILIP A | 2007-09-13 | — | — | US | disclosed |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CARPINO PHILIP A | 2007-09-13 | — | — | US | disclosed |
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232823-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| EP-1636233-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108728-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248881-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248881-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885KCNH2 3162/4885 |
| US-20070213334-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885KCNH2 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.